Alexion Pharmaceuticals plans follow-on stock offering

By Angela McDaniels

Seattle, Nov. 14 - Alexion Pharmaceuticals, Inc. plans to offer 2.5 million shares of its common stock in a public offering, according to a company news release.

Goldman, Sachs & Co. and Morgan Stanley & Co. Inc. are joint bookrunners for the offering, with Bear, Stearns & Co. Inc, Cowen and Co., LLC, Credit Suisse and Piper Jaffray & Co. as co-managers.

The underwriters will be granted an over-allotment option for 375,000 shares.

The Chesire, Conn.-based biotechnology company's stock closed down on Tuesday at $41.82 (Nasdaq: ALXN).

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.